ExacTcell Platform
Viral-Induced Cancers
Key Facts
About Tevogen Bio
Tevogen Bio is a clinical-stage biotech focused on developing accessible, off-the-shelf T cell therapies for oncology, virology, and neurology. Its core achievement is the ExacTcell platform, which selects and expands naturally occurring, unmodified cytotoxic T lymphocytes (CTLs) for precise targeting of diseased cells. The company's strategy is to leverage this scalable, allogeneic technology to address large patient populations with commercially attractive and economically viable therapies. Its lead program, TVGN-489, is in Phase 1/2 trials for COVID-19 and Long COVID.
View full company profileAbout Tevogen Bio
Tevogen Bio is a clinical-stage biotech focused on developing accessible, off-the-shelf T cell therapies for oncology, virology, and neurology. Its core achievement is the ExacTcell platform, which selects and expands naturally occurring, unmodified cytotoxic T lymphocytes (CTLs) for precise targeting of diseased cells. The company's strategy is to leverage this scalable, allogeneic technology to address large patient populations with commercially attractive and economically viable therapies. Its lead program, TVGN-489, is in Phase 1/2 trials for COVID-19 and Long COVID.
View full company profileAbout Tevogen Bio
Tevogen Bio is a clinical-stage biotech focused on developing accessible, off-the-shelf T cell therapies for oncology, virology, and neurology. Its core achievement is the ExacTcell platform, which selects and expands naturally occurring, unmodified cytotoxic T lymphocytes (CTLs) for precise targeting of diseased cells. The company's strategy is to leverage this scalable, allogeneic technology to address large patient populations with commercially attractive and economically viable therapies. Its lead program, TVGN-489, is in Phase 1/2 trials for COVID-19 and Long COVID.
View full company profile